MariMed (MRMD) director reports vesting of 247,385 RSUs into stock

Rhea-AI Filing Summary

MariMed Inc. director Edward Gildea reported the conversion of restricted stock units into common stock. On December 15, 2025, 247,385 restricted stock units were settled into 247,385 shares of MariMed common stock at a stated price of $0 per share under transaction code M.

After this transaction, Gildea directly owned 905,208 shares of MariMed common stock. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 as payment in stock instead of cash for a portion of his fees for serving on the company’s board of directors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gildea Edward J

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/15/2025		M		247,385	A	$0(1)	905,208	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/15/2025		M			247,385	(2)	(2)	Common Stock, par value $.001 per share	247,385	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs were granted on December 5, 2025 and vested in full on December 15, 2025 in accordance with the terms of the award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ Edward Gildea	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) report for December 15, 2025?

MariMed director Edward Gildea reported the conversion of 247,385 restricted stock units (RSUs) into 247,385 shares of MariMed common stock at a stated price of $0 per share, coded as transaction type M.

How many MariMed (MRMD) shares does director Edward Gildea own after this Form 4 transaction?

Following the reported RSU conversion, director Edward Gildea beneficially owns 905,208 shares of MariMed common stock in direct ownership.

What were the terms of the RSUs reported in this MariMed (MRMD) Form 4?

The filing states that the RSUs convert to shares of common stock on a one-for-one basis. A total of 247,385 RSUs were involved, each converting into one share of MariMed common stock with a stated price of $0 per share, and the number of derivative securities beneficially owned after the transaction is 0.

When were the restricted stock units for the MariMed (MRMD) director granted and when did they vest?

The RSUs were granted on December 5, 2025 and vested in full on December 15, 2025 in accordance with the terms of the award agreement between MariMed and the reporting person.

Why did the MariMed (MRMD) director receive RSUs instead of cash?

The filing explains that the RSUs were granted in lieu of cash as payment for a portion of the reporting person’s fees for serving on MariMed’s board of directors.

Does the MariMed (MRMD) director still hold any RSUs after this transaction?

No. Table II shows that the number of derivative securities beneficially owned following the reported transaction is 0, indicating that the 247,385 RSUs were fully converted into common stock.